MetaCap

Tectonic Therapeutic Inc. (TECX)

NASDAQ: TECXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

20.73-0.31 (-1.47%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TECX stock chart

Technical analysis

Key statistics

All statistics
Market cap
$405.26M
EPS (TTM)
-$4.63
52-week range
16.77 – 39.53
Day range
20.41 – 21.57
Volume / Avg
268.83K / 212.16K
Beta
—

52-week range

$16.77$39.53

TECX stock today

Shares of Tectonic Therapeutic (TECX) finished lower on Nov 20 at $20.73, a drop of 1.47% or $0.31 per share, versus the S&P 500's 3.70% decline. At this level, TECX sits near the bottom of its 52-week range of $16.77 to $39.53: 47.6% below the high, set on Jul 6, 2026 and 23.6% above the low. TECX is down 0.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 8.1%.

Tectonic Therapeutic has posted a net loss over the last twelve months (EPS of -$4.63), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Tectonic Therapeutic

Company profile

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Alise S. Reicin M.D., Ph.D.
Headquarters
Watertown, MA
Employees
60
IPO year
2018

Financial highlights

Full financials

Tectonic Therapeutic reported a net loss of $74.2 million, compared with a loss of $58.0 million a year earlier. Diluted earnings per share came in at -$4.05.

Tectonic Therapeutic annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-74.15M$-57.98M$-42.82M$-105.89M$-119.13M
EPS (diluted)$-4.05$-6.83$-33.76$-2.42$-2.78

Analyst forecast

Forecast

Consensus (10 analysts)

strong_buy

Avg. price target

$71.00+242.50%

  • Strong buy 1
  • Buy 8
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $26.00High $93.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-1.08 vs $-1.38
Surprise
+21.74%

TECX news

All TECX news

Tectonic Therapeutic peers

Health Care sector
TECX peer companies
CompanyPrice% ChgMarket capCompare
TVGNTevogen Inc.5.90-6.35%$405.20Mvs TECX
CADLCandel Therapeutics Inc.5.04-1.75%$395.37Mvs TECX
PROKProKidney Corp. Class A1.04-1.89%$415.21Mvs TECX
IRLAIRulya Therapeutics Inc.39.88-0.15%$432.36Mvs TECX
FENCFennec Pharmaceuticals Inc.13.09-2.68%$462.14Mvs TECX
ALECAlector Inc.2.34+1.52%$347.63Mvs TECX
RGNXREGENXBIO Inc.7.16-0.28%$473.44Mvs TECX
SANASana Biotechnology Inc.1.59-8.62%$476.42Mvs TECX

Indexes, lists and sector

Tectonic Therapeutic stock FAQ

What is Tectonic Therapeutic's stock price today?

TECX last traded at $20.73 as of Nov 20, 4:00 PM EST, down 1.47% on the day. Prices are delayed at least 15 minutes.

Does Tectonic Therapeutic pay a dividend?

No. Tectonic Therapeutic does not currently pay a regular cash dividend.

Who is Tectonic Therapeutic's CEO?

Dr. Alise S. Reicin M.D., Ph.D. is the chief executive officer of Tectonic Therapeutic Inc., which has about 60 employees.

Has TECX ever split its stock?

Yes. The most recent TECX stock split was a 1-for-12 split on Jun 21, 2024.

What is the TECX 52-week high?

The 52-week high for TECX is $39.53 and the 52-week low is $16.77. The stock is currently 47.6% below its high.

Compare TECX